The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
Naiyer A. Rizvi
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; MedImmune; Roche/Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer
Laura Quan Man Chow
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; University of Washington
Hossein Borghaei
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer
Yun Shen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (B)
Christopher Harbison
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Suresh Alaparthy
Employment or Leadership Position - Bristol-Myers Squibb
Allen C. Chen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Scott N. Gettinger
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb